Abstract
Human African trypanosomiasis (HAT) is a parasitic neglected tropical disease that affects 10,000 patients each year. Current treatments are sub-optimal, and the disease is fatal if not treated. Herein, we report our continuing efforts to repurpose the human phosphodiesterase 4 (hPDE4) inhibitor piclamilast to target trypanosomal phosphodiesterase TbrPDEB1. We prepared a range of substituted heterocyclic replacements for the 4-amino-3,5-dichloro-pyridine headgroup of piclamilast, and found that these compounds exhibited weak inhibitory activity of TbrPDEB1.
Keywords:
Drug discovery; Neglected Disease; Phosphodiesterases; Piclamilast; TbrPDEB1; TbrPDEB2; Trypanosoma brucei.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
3',5'-Cyclic-AMP Phosphodiesterases / antagonists & inhibitors*
-
3',5'-Cyclic-AMP Phosphodiesterases / metabolism
-
Benzamides / chemistry
-
Benzamides / pharmacology
-
Catechols / chemistry*
-
Catechols / pharmacology*
-
Drug Discovery
-
Humans
-
Models, Molecular
-
Phosphodiesterase 4 Inhibitors / chemistry
-
Phosphodiesterase 4 Inhibitors / pharmacology
-
Protozoan Proteins / antagonists & inhibitors*
-
Protozoan Proteins / metabolism
-
Pyridines / chemistry
-
Pyridines / pharmacology
-
Trypanocidal Agents / chemistry*
-
Trypanocidal Agents / pharmacology*
-
Trypanosoma brucei brucei / drug effects*
-
Trypanosoma brucei brucei / enzymology
-
Trypanosomiasis, African / drug therapy
-
Trypanosomiasis, African / parasitology
Substances
-
Benzamides
-
Catechols
-
Phosphodiesterase 4 Inhibitors
-
Protozoan Proteins
-
Pyridines
-
Trypanocidal Agents
-
3',5'-Cyclic-AMP Phosphodiesterases
-
PDEB1 protein, Trypanosoma brucei
-
catechol
-
piclamilast